Gene News and Research

Latest Gene News and Research

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

Study demonstrates BRACAnalysis testing for women with breast carcinoma in situ

Myriad Genetics, announced today that an article entitled "Prevalence of BRCA1 and BRCA2 Mutations In Women With Carcinoma In Situ of the Breast Referred for Genetic Testing" will appear in the December 2010 issue of the journal Cancer Prevention Research.

16 Dec 2010

New findings says TRIM24 protein plays active role in breast cancer formation

The recently identified TRIM24 protein plays an active role in pushing normal breast cells into rapid cell proliferation and, potentially, into breast cancer.

16 Dec 2010

Research: Stem cell culture on soft substrate maintain homogeneous pluripotent colonies

In a paper published in the journal PLoS One, the researchers demonstrated that culturing mouse embryonic stem cells on a soft gel rather than on a hard plate or dish keeps them in their pluripotent state, a ground state with the ability to become any type of tissue.

16 Dec 2010

PEG-Prom encased nanoparticle aids in cancer detection and treatment

In a proof of principal study in mice, scientists at Johns Hopkins and the Virginia Commonwealth University have shown that a set of genetic instructions encased in a nanoparticle can be used as an "ignition switch" to rev up gene activity that aids cancer detection and treatment.

16 Dec 2010

Novel adenovirus-based gene therapy for renal cell carcinoma

Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.

16 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Clinical Investigation – ground-breaking new launch from Future Science

In recognition of the methodology, progress and outcome of clinical trials, Future Science has announced the launch of the definitive title Clinical Investigation. The journal is the latest addition to the Future Science’s collection of titles addressing those areas that most impact our daily lives (available at www.future-science.com). Future Science is part of London-based Future Science Group.

15 Dec 2010

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Repligen Corporation today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA"). RG3039, our lead compound, is an inhibitor of an RNA processing enzyme which targets increased production of SMN, a protein of deficient levels in patients with SMA.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

The Charité - Medical University of Berlin has today begun the implementation of the clinical study phase I/II with the renal cancer medication MGN1601 (ASET Study). With this MOLOGEN AG product, an innovative cell-based gene therapy for the treatment of advanced renal cancer is entering the first important test phase.

15 Dec 2010

African sleeping sickness parasite's previously unrecognized extreme social behavior discovered

Long considered a freewheeling loner, the Trypanosoma brucei parasite responsible for African sleeping sickness has revealed a totally unexpected social side, opening a potential chink in the behavioral armor of this and other supposedly solitary human parasites, according to research presented at the American Society for Cell Biology's 50th Annual Meeting in Philadelphia.

15 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

Researchers develop synthetic circuits to detect changes in state of health

Using yeast cells, a group of researchers at the University of Gothenburg, Sweden, has taken a groundbreaking step towards being able to build complex systems in the future where the body's own cells help to keep us healthy.

15 Dec 2010

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the publication of a paper in Cancer Cell that illuminates the mechanism by which 2-hydroxyglutarate (2HG), and the mutations in the metabolic genes IDH1 and IDH2 that produce it, may be driving the growth of tumors in patients with acute myeloid leukemia (AML).

15 Dec 2010

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

Tumor suppressor p53 may serve as 'Guardian against Genome Reprogramming'

A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."

15 Dec 2010

FP/TMEM127 gene germline mutations associated with adrenal gland tumors

Analysis has identified variations of a gene that are associated with a type of tumor that forms within the adrenal gland, according a study in the December 15 issue of JAMA. The age group in which these variations were found are frequently excluded from genetic screening models for this type of tumor.

15 Dec 2010

Gene News and Research

Latest Gene News and Research

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Study demonstrates BRACAnalysis testing for women with breast carcinoma in situ

New findings says TRIM24 protein plays active role in breast cancer formation

Research: Stem cell culture on soft substrate maintain homogeneous pluripotent colonies

PEG-Prom encased nanoparticle aids in cancer detection and treatment

Novel adenovirus-based gene therapy for renal cell carcinoma

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Scientists discover potential strategy for pancreatic cancer therapy

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Clinical Investigation – ground-breaking new launch from Future Science

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Charité begins implementation of MGN1601 clinical phase I/II study in renal cancer

African sleeping sickness parasite's previously unrecognized extreme social behavior discovered

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Researchers develop synthetic circuits to detect changes in state of health

Study broadens understanding of role of IDH1 and IDH2 mutations in AML

Myotec, Hybrid merge to form PsiOxus Therapeutics

Tumor suppressor p53 may serve as 'Guardian against Genome Reprogramming'

FP/TMEM127 gene germline mutations associated with adrenal gland tumors

eBook: Using iPSCs models for human disease research and drug discovery eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting